- Home
- NEPH vs BTAI Comparison
NEPH vs BTAI Comparison
Compare NEPH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- BTAI
- Stock Information
- Founded
- NEPH 1997
- BTAI 2017
- Country
- NEPH United States
- BTAI United States
- Employees
- NEPH N/A
- BTAI N/A
- Industry
- NEPH Medical/Dental Instruments
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- NEPH Health Care
- BTAI Health Care
- Exchange
- NEPH Nasdaq
- BTAI Nasdaq
- Market Cap
- NEPH 15.9M
- BTAI 18.1M
- IPO Year
- NEPH 2004
- BTAI 2018
- Fundamental
- Price
- NEPH $1.60
- BTAI $0.36
- Analyst Decision
- NEPH Buy
- BTAI Buy
- Analyst Count
- NEPH 1
- BTAI 4
- Target Price
- NEPH $5.00
- BTAI $2.81
- AVG Volume (30 Days)
- NEPH 9.9K
- BTAI 1.3M
- Earning Date
- NEPH 03-06-2025
- BTAI 03-11-2025
- Dividend Yield
- NEPH N/A
- BTAI N/A
- EPS Growth
- NEPH N/A
- BTAI N/A
- EPS
- NEPH N/A
- BTAI N/A
- Revenue
- NEPH $13,546,000.00
- BTAI $2,276,000.00
- Revenue This Year
- NEPH N/A
- BTAI $131.45
- Revenue Next Year
- NEPH $9.13
- BTAI $45.65
- P/E Ratio
- NEPH N/A
- BTAI N/A
- Revenue Growth
- NEPH 0.03
- BTAI 83.25
- 52 Week Low
- NEPH $1.36
- BTAI $0.30
- 52 Week High
- NEPH $3.83
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- NEPH 55.59
- BTAI 45.04
- Support Level
- NEPH $1.48
- BTAI $0.33
- Resistance Level
- NEPH $1.57
- BTAI $0.39
- Average True Range (ATR)
- NEPH 0.06
- BTAI 0.06
- MACD
- NEPH 0.01
- BTAI -0.00
- Stochastic Oscillator
- NEPH 71.43
- BTAI 16.80
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.